贝达药业：近日，MCLA-129与恩沙替尼联合用药I/II期临床研究已完成首例受试者入组

Core Viewpoint - The development of innovative drugs is a long-term and challenging exploration, with MCLA-129 showing valuable clinical data in the field of advanced non-small cell lung cancer [2] Group 1: Company Updates - Beida Pharmaceutical announced that the first subject has been enrolled in the I/II phase clinical study of MCLA-129 combined with Ensartinib [2] - The company aims to further validate the clinical potential of this combination therapy in collaboration with research institutions and experts [2] Group 2: Industry Insights - MCLA-129 is an EGFR/c-MET bispecific antibody, which provides additional treatment options for patients with advanced solid tumors characterized by MET amplification or overexpression [2]